Acrux Limited (AU:ACR)
ASX:ACR
Want to see AU:ACR full AI Analyst Report?
ACR Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.03
Previous CloseN/A
Volume88.57K
Average Volume (3M)120.95K
Market Cap
AU$5.13M
Enterprise ValueAU$6.80M
Total Cash (Recent Filing)AU$863.00K
Total Debt (Recent Filing)AU$3.63M
Price to Earnings (P/E)9.3
Beta0.12
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,260,700
10 Day Avg. Volume76,863
30 Day Avg. Volume120,955
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)5.51
Price to Sales (P/S)4.73
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing ModelAcrux's licensing-driven model generates royalties and milestone payments via commercial partners, keeping capital intensity low. This asset-light structure supports scalable revenue if partners execute, preserves cash versus direct commercialization, and aligns Acrux with recurring royalty economics over time.
Strong Revenue Growth TrendReported high revenue growth metrics indicate rising royalty or product-related receipts and improving market traction. Sustained top-line expansion provides a foundation for future margin recovery and cash generation as fixed costs are spread and licensing income scales with partner sales over subsequent quarters.
High Gross Margin ProfileAcrux's reported 100% gross margin in 2025 suggests revenue is largely high-margin licensing income with minimal direct COGS. Persistently elevated gross margins create operating leverage potential: once OPEX and cash burn are controlled, incremental royalties can flow directly to EBITDA and support durable profitability improvements.
Bears Say
High Financial LeverageA debt-to-equity ratio of 3.55 indicates material leverage that reduces financial flexibility. High debt increases refinancing and interest burden risks, limits capacity to absorb revenue volatility, and constrains investment in growth or R&D, particularly problematic given ongoing negative operating cash flows.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows signal cash burn and liquidity pressure, forcing reliance on external financing or milestone receipts. This undermines the company's ability to fund operations, reduce debt, or invest in commercialization without dilutive or costly financing over the medium term.
Ongoing Net Losses And Negative MarginsDespite top-line gains, continued net losses and negative EBIT reveal structural cost or operating inefficiencies. If operating expenses remain elevated versus revenue, translating revenue growth into sustained profitability will be challenging and may require significant cost control or business-model adjustments.
Acrux News
ACR FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest share price was AU$0.01 and its highest was AU$0.03 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is AU$5.13M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Aug 21, 2026 which is in 92 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of AU$0.06 which represents an annual dividend yield of N/A. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 513,260,700 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in AU:ACR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-211.88%
Trailing 12-Months
Asset Growth
-34.57%
Trailing 12-Months
Company Description
Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―
Options Prices
Currently, No data available
---